SNOA vs. GLYC, AFMD, SPRB, HCWB, SYBX, EGRX, NRSN, MTVA, IPA, and GOVX
Should you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include GlycoMimetics (GLYC), Affimed (AFMD), Spruce Biosciences (SPRB), HCW Biologics (HCWB), Synlogic (SYBX), Eagle Pharmaceuticals (EGRX), NeuroSense Therapeutics (NRSN), MetaVia (MTVA), ImmunoPrecise Antibodies (IPA), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry.
Sonoma Pharmaceuticals vs.
GlycoMimetics (NASDAQ:GLYC) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment, community ranking and earnings.
GlycoMimetics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -26.82%. Sonoma Pharmaceuticals' return on equity of -68.98% beat GlycoMimetics' return on equity.
GlycoMimetics presently has a consensus price target of $8.00, suggesting a potential upside of 2,612.78%. Given GlycoMimetics' stronger consensus rating and higher probable upside, equities analysts plainly believe GlycoMimetics is more favorable than Sonoma Pharmaceuticals.
75.2% of GlycoMimetics shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 8.7% of GlycoMimetics shares are held by insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
GlycoMimetics has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.
In the previous week, GlycoMimetics had 4 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 4 mentions for GlycoMimetics and 0 mentions for Sonoma Pharmaceuticals. GlycoMimetics' average media sentiment score of 0.25 beat Sonoma Pharmaceuticals' score of 0.00 indicating that GlycoMimetics is being referred to more favorably in the media.
GlycoMimetics received 99 more outperform votes than Sonoma Pharmaceuticals when rated by MarketBeat users. However, 67.50% of users gave Sonoma Pharmaceuticals an outperform vote while only 58.55% of users gave GlycoMimetics an outperform vote.
Sonoma Pharmaceuticals has higher revenue and earnings than GlycoMimetics.
Summary
GlycoMimetics beats Sonoma Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Sonoma Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sonoma Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SNOA) was last updated on 2/22/2025 by MarketBeat.com Staff
